THANZ/LinkedIn
Mar 13, 2026, 16:15
New Evidence From the COBRRA Trial in Acute VTE – THANZ
Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published on NEJM:
“Congratulations to our THANZ members on a NEJM publication!
This international randomized trial (COBRRA) shows substantially lower bleeding risk with apixaban compared with rivaroxaban in acute VTE – evidence that matters at the bedside.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté
Read the Full Article on NEJM
Other posts featuring THANZ on Hemostasis Today.
-
Apr 29, 2026, 16:53Chokri Ben Lamine: IV Iron Showdown – FCM vs Ferric Derisomaltose vs Iron Dextran
-
Apr 29, 2026, 16:46Deep Vein Thrombosis Risk in Jobs with Prolonged Sitting – NBCA
-
Apr 29, 2026, 16:41Vikramaditya Gangakar: Essential Pharmacy Facts You Should Know About Aspirin
-
Apr 29, 2026, 16:17W. Alberto Sifuentes Giraldo: Non-Criteria Manifestations of Antiphospholipid Syndrome
-
Apr 29, 2026, 16:12Mavis Agnes Kisakye: Concluding a Successful Entrepreneurs Training for Empowering Ptients’ Mothers
-
Apr 29, 2026, 15:48Kriti Batni: Happy to Share on Our Chapter Being Published in Medicine Update 2026
-
Apr 29, 2026, 15:46Dima Shulkin: Comparing HALP and PIV for Mortality Prediction in ACS
-
Apr 29, 2026, 15:44Sonal Sonu: Securing First Prize in Research Oral Presentation at the CME
-
Apr 29, 2026, 15:43Andrew Shaw: Long COVID First Diagnostic Classification with 69% accuracy